Diamyd to Initiate Ph3 DIAGNODE-3 Trial in Europe; First Patient Dosed with CRISPR and ViaCyte’s VCTX210 in Ph1 Trial; Know Labs Bio-RFID Device Receives IRB Approval

A series of cardiometabolic-related news items have been observed: Diamyd Medical announced it will proceed to initiate its Ph3 T1DM vaccine trial (DIAGNODE-3) in Europe; CRISPR and ViaCyte announced they have dosed the first patient in their Ph1 VCTX210 trial; and Know Labs recently announced that it received IRB approval for a new trial of its non-invasive glucose monitor. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.